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Bone marrow stem cell therapy has emerged as a promising approach to improve healing of the infarcted myocardium. Despite
initialexcitement, recent clinicaltrials usingnon-homogenousstem cells preparations showedvariable andmixed results. Selected
CD133+ hematopoieticstemcellsarecandidatecellswithhighpotential.Herein,wereporttheone-yearsafetyanalysisontheinitial
20 patients enrolled in the COMPARE-AMI trial, the ﬁrst double-blind randomized controlled trial comparingthe safety, eﬃcacy,
and functional eﬀect of intracoronary injection of selected CD133+ cells to placebo following acute myocardial infarction with
persistent left ventricular dysfunction. At one year, there is no protocol-related complication to report such as death, myocardial
infarction, stroke, or sustained ventricular arrhythmia. In addition, the left ventricular ejection fraction signiﬁcantly improved at
four months as compared to baseline and remained signiﬁcantly higher at one year. These data indicate that in the setting of the
COMPARE-AMItrial,theintracoronaryinjectionofselected CD133+ stemcells issecure andfeasibleinpatients withleft ventricle
dysfunction followingacute myocardial infarction.
1.Introduction
Despite improvements in survival rate after myocardial
infarction (MI) with recent medical and surgical advances
[1], the reduced heart function attributed to irreversible loss
of viable cardiomyocytes remains a major clinical problem
[2]. Intracoronary (IC) injection of progenitor cells emerged
as a valuable therapeutical approach to improve healing
of the ischemic heart. Despite the use of various experi-
mental protocols with mixed cells showing mixed results
[3], four recent meta-analyses of bone marrow stem cells
(BMSCs) transplantation in the setting of acute MI proved
the feasibility and safety and demonstrated a slight but
positive functional eﬀect [4–7]. However, there is currently
uncertainty as to which of the BMSC population is most
potent in stimulating angiogenesis and cardiac repair. The
hematopoietic CD133+ cells possess high engraftment, mul-
tipotent, and angiogenic capacity and appear to be valuable
for cardiac repair in experimental myocardial infarction [8–
11].2 Bone Marrow Research
Table 1: Demographic and clinical characteristics. BMI indicates
body mass index, CAD coronary artery disease, PCI percutaneous
coronary intervention, CK creatinine kinase, and CK-MB creatine
kinase-muscleand brain.
Age (yrs) 52,2 ± 8.9
Male (%) 90
BMI 28 ±5.7
Diabetes (%) 15
Hypertension (%) 35
Hyperlipidemia (%) 20
Smoking(%) 70
Family history of CAD (%) 15
Door to balloon (Min) 123.6 ±97.4
PCI to injection (days) 6.4 ± 2.2
Killip class I: 95; II: 5
MaximalST elevation (mm) 11.2 ± 5.5
Q waves on admission(%) 55
Peak troponin T (UI/mL) 10.48 ±8.34
Peak CK (UI/mL) 2744 ±2193
Peak CK-MB (UI/mL) 341 ±260.7
In a phase I study, Bartunek et al. tested the IC injection
of CD133+ cells in patients following acute MI and demon-
strated a signiﬁcant improvement of the left ventricular
(LV) function and perfusion as compared to controls [12].
However, they noted in the treated group an increase of
coronary eventswith greater in-stent proliferationand larger
luminallossinthenonstentedsegmentsoftheinfarct-related
(IR) artery [13]. Of note, these data were obtained from
retrospective analysis and they lack randomized controls.
Hence, we designed the COMPARE-AMI trial, the ﬁrst ran-
domized, double-blind, placebo-controlled phase II single
center study comparing the IC injection of CD133+ cells to
placebo on the cardiac repair in patients with acute MI and
persistent LV dysfunction [14, 15]. Herein, we report the
one-year safety analysis on the ﬁrst randomized patients.
2.Methods
2.1. Study Design and Objectives. COMPARE-AMI study is a
single-center, randomized, prospective, double-arm,double-
blind, placebo-controlled phase II clinical trial investigating
the feasibility, safety, and eﬃcacy of the IC administration of
selected autologous CD133+-enriched hematopoietic BMSC
versus placebo in patients following acute MI with persistent
dysfunctional myocardium despite successful catheter reper-
fusion. The ﬂow chart of the trial is detailed in Figure 1.
The primary end point of the study is a composite of
safety and eﬃcacy end points aiming to determine the
change in the coronary atherosclerotic burden progression
proximal and distal to the stented segment of the culprit
artery at 4 months as compared to baseline, and the change
in the left ventricle ejection fraction (LVEF) at 4 months
relative to baseline. The secondary end points include
t h eo c c u r r e n c eo fam a j o ra d v e r s ec a r d i a ce v e n t( M A C E )
deﬁned as death, MI, stroke, and target vessel revascularisa-
tion (TVR) or the occurrence of major arrhythmias deﬁned
as sustained ventricular arrhythmia or survived sudden
death. Patients are followed for 2 years, and the data will
be unblinded 12 months after the randomization of the last
patient.
2.2. Study Populationand Protocol. Inbrief, patientsbetween
30 and 75 years are eligible if they presented an acute ST
elevation MI successfully reperfused by means of coronary
stent implantation and demonstrated a substantial persis-
tent LV dysfunction deﬁned by a LVEF ≤50% but ≥25%
on echocardiography obtained within 48 hours after the
successful reperfusion therapy. Written informed consent
is obtained within 7 days after the onset of acute MI if
the patient is free of any exclusion criteria such as known
previous MI, cardiogenic shock, chronic cardiomyopathy,
liver disease, renal failure, concomitant disease with a life
expectancy of less than 1 year, alcohol or drug dependency,
contraindication for bone marrow (BM) aspiration, blood
transfusion in the previous 24 hours, hematopoietic disease,
chronic inﬂammatory disease, malignancy, stroke in the
previous 3 months, or transient ischemic attack in the
previous 24 hours. The study protocol was approved by
Health Canada (CTA 113925 and ITA 123840) and by
institutional ethics review board.
Until September 2009, 20 patients were successfully
enrolled in the trial. A total of 18 patients completed the 4-
monthfollowupand13patientsreached the1-yearfollowup.
All patients underwent BM aspiration 3 to 7 days after
receiving reperfusion therapy for acute MI. An average
volume of 100mL of the BM was obtained and transferred
immediately to the cell processing laboratory where patients
were randomly assigned to receive placebo medium (normal
saline containing 10% autologous plasma) or autologous
CD133+ cells. CD133+ progenitor cells for this trial are
immunomagnetically selected using the CliniMACS
￿ sys-
tem (Miltenyi Biotec GmbH) according to manufacturer’s
protocols. Within 12 hours of BM harvest, the study suspen-
sion is sent back to the cardiac catheterisation laboratory for
IC administration in the IR artery using intermittentballoon
inﬂation as previously described in [16]. In summary, the
infusate is deliveredvia anover-the-wire percutaneoustrans-
luminal coronary angioplasty catheter over 3 min of balloon
inﬂation within the previously placed intracoronary stent.
Three minutes of reperfusion are incorporated after each
cycle of cell infusion. A total of 4 cycles are given. Patients
are routinely discharged 48 hours following the infusion
procedure with the usual postacute MI care medications.
Myocardial functional evaluation is done with echocar-
diography, cardiac magnetic resonance imaging (MRI),
left ventricular angiography, echocardiography, technetium
99m sestamibi single photon emission computed tomog-
raphy, and positron emission tomography with [17]ﬂ u -
orodeoxyglucose at baseline and 4 months of followup.
Cardiac MRI and echocardiography are repeated at 1 year of
followup.Bone Marrow Research 3
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Figure 1: Flow chart of the COMAPRE-AMI trial. MI indicates myocardial infarction, PCI percutaneous coronary intervention, LVEF left
ventricular ejection fraction, IC intracoronary, LV left ventricle, IVUS, intravascular ultrasound, FFR fractional ﬂow reserve, PET positron
emissiontomography, MIBI technetium 99m sestamibi, MRI magnetic resonance imaging, and ECG electrocardiogram.
Table 2: Biological markers after IC injection, no change over time (All P = NS). WBC indicates white blood cells count, CRP C-reactive
protein, CK creatinine kinase, and CK-MB creatine kinase-muscleand brain.
Baseline (end of the IC injection) 30min 60min 6hrs Day 1
WBC 8.12 ±1.68 .65 ±1.96 8.92 ± 2.31 7.74 ±1.94 7.29 ±1.69
CRP 11.09 ±12.16 10.15 ±8.56 12.15 ± 12.81 3 .18 ±14.24 13.08 ±13.96
Troponin T 0.83 ±1.02 0.88 ±1.07 0.91 ± 1.13 0.8 ± 0.95 0.66 ±0.84
CK 167.4 ±95.6 176.5 ±99 204 ±135.9 171.5 ±85.3 160.4 ±81.97
CK-MB 46.8 ±22.25 1 .33 ±28.17 55.56± 27.58 72 ± 40.28 60.7 ±39.90
Table 3: In-hospital, 4- and 12-month reported adverse events.
SVT indicates sustained ventricular tachycardia, ICD implantable
cardioverter-deﬁbrillator, BMS bare metal stent DES drug-eluting
stent, BM bone marrow, and IC intracoronary.
In-hospital 4 months 12 months
Mortality (n)0 0 0
Re-infarct (n)0 0 0
Stroke (n)0 0 0
SVT/ICD (n)0 0 0
Heart failure (n)2 1 1
Stent thrombosis (n)0 0 0
In-BMS restenosis/occlusion 0 3 0
In-DES restenosis/occlusion 0 0 0
Bleeding/transfusion (n) 2/0 0/0 0/0
BM harvest related (n) 0 NA NA
IC Injection related (n) 0 NA NA
2.3. Safety Evaluation. T od e t e r m i n et h es a f e t yo ft h eI C
injection of CD133+ cell suspension, standard laboratory
tests including white blood cells (WBC) count, C-reactive
protein (CRP), creatine kinase (CK), and creatine kinase-
muscle and brain (CK-MB) type and troponin T measure-
ments were performed before, 30 and 60 minutes, 6 hours,
and 24 hours after the IC injections. In addition, all patients
were continuouslymonitored until discharge and underwent
24-hour ECG monitoring at baseline, 1, 4, and 12 months
after the procedure. Furthermore, a quantitative coronary
angiography, pressure-derived fractional ﬂow reserve (FFR),
and an IC ultrasonography were performed in the IR artery
and a remote artery at baseline and 4-month followup.
2.4. Statistical Analysis. Baseline demographic and clinical
variables were collected for all patients. Invasive and non-
invasive analyses were performed by operators blinded to
all clinical and other functional data. Data are presented
as mean ± standard deviation or median and interquartile
range when appropriate. Continuous variables were ana-
lyzed using Student’st-test. Fullyparameterized longitudinal
mixed eﬀect models were built for echocardiographic mea-
surement, including a coeﬃcient for each point in time at
baseline, 4 and 12 months (the MIXED procedure in SAS
software, version9.1;SASInstitute,Cary, NC).These models4 Bone Marrow Research
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Figure 2: Left ventricular ejection fraction improvement assessed
byechocardiography foreachrandomizedpatientatbaselinebefore
treatment (n = 20), 4 months (n = 18) and 12 months of followup
(n = 13). Cardiac function was signiﬁcantly improved at 4 and 12
months(P<. 001).LVEF indicates left ventricular ejection fraction.
account for the correlation between repeated measurements
inthesame patient.Forall analyses, P< . 05were considered
statistically signiﬁcant.
3.Results
3.1. Clinical Characteristics. Herein, we are presenting the
one-year safety analysis of the ﬁrst twenty patients random-
ized and treated in the COMPARE-AMI trial. The demo-
graphic and clinical characteristics are showed in Table 1.
The mean age was 52.2 ± 8.9 years with a predominance
of males (90%) and the culprit lesion was located on the
left anterior descending artery in 90%. A complete occlusion
was noted in the proximal segment of the IR artery in 65%
of cases. Maximum troponin T and CKMB were 10.48 ±
8.34Ug/Land341 ± 260.7U/L,respectively,suggestinglarge
infarcts. All patients underwent a successfully reperfusion
with stenting using a drug-eluted stent (DES) in 75%
or a bare metal stent (BMS) in 25% of cases. Adjuvant
medical therapy included aspirin, clopidogrel, β-blockers,
angiotensin-converting enzyme inhibitors, and statins.
3.2. Safety Analysis. BM harvests were well tolerated by all
patients without any related complication. For an average of
10×106 CD133+ cells, we obtained a mean recovery of more
than 95% when comparing before and after cell separation.
Moreover, we obtained a mean purity higher than 65% for
selected CD133+ cells. Cell purity is validated using ﬂow
cytometric analysis using standard techniques. Cell viability
is assessed by trypan bleu exclusion, which is always greater
than 95%. The IC injection was performed 6.4 ± 2.2d a y s
after stenting. Two patients had a small hematoma at the
arterial access site (one radial and one femoral) that did not
require any speciﬁc treatment. As compared to baseline, no
signiﬁcant diﬀerences in the WBC count, CRP, CK, CK-MB,
and troponin T levels were found at 24 hours (Table 2). In
addition, in-hospital continuous ECG monitoring did not
reveal any episode of sustained ventricular arrhythmia, and
only two patients had at least one episode of nonsustained
ventricular tachycardia (NSVT). The serial 24-hour holter
ECG monitoring performed at 1, 4, and 12 months revealed
a small increase in the number of patients who had at least
one run of a NSVT (ﬁve patients at 4 and 12 months as
compared to two patients at baseline). In addition, despite
a low number of isolated ventricular premature beats (VPB)
at baseline of 6.5 [1.8, 14.8] and after treatment of 4.5
[3.0, 10.5], we observed an important increase at 1-month
followup with 30.0 [13.0, 129.5]. Number of VPBs decreased
thereafterat4monthswithamedian of9.0[3.0,117.0].Until
one-year followup, no spontaneous sustained ventricular
arrhythmias or survived sudden death were noted and no
patient required an implantable cardioverter-deﬁbrillator
(ICD).
Furthermore, up to 12-month followup no MACE, angi-
na, or stent thrombosis were reported (Table 3). During the
initial hospitalization and before randomization, 2 patients
had an episode of heart failure that required diuretics. Of
note, one patient stopped for one week his medication and
was hospitalized 3 months after his randomization for heart
failure with a temporary drop of his LVEF down to 15%.
Finally, at 4-month followup, restenting was necessary in 3
patients to treat in-BMS restenosis. No in-DES restenosis or
de novo lesions in the IR artery were observed. Moreover,
despite the signiﬁcant lower pressure-derived FFR in the
culprit artery as compared to the nonculprit artery at
baseline:, 0.88 ± 0.05 versus 0.96 ± 0.04, P<. 001, no
signiﬁcant modiﬁcation was noted in the delta FFR at 4-
month followupascomparedtobaseline in theculpritversus
nonculprit artery (−3.7%±5.4versus−1.1%±4.6r es p .,P =
.148)suggestingtheabsenceoflocalordiﬀuseaccelerationof
coronary atherosclerosis.
3.3. LV Function Assessment after Randomization. As shown
in Figure 2, echocardiographic assessment of the LVEF
demonstrated a signiﬁcant improvement at 4-month fol-
lowup (n = 18) as compared to baseline (51.1% ± 2.5 versus
41.2%±1.1resp.,P<. 001).Thisimprovementwassustained
at 12-month followup (52.3%±2.0,P<. 001versusbaseline,
n = 13).
4.Discussion
In the setting of acute MI, several studies [4–7]h a v es h o wna
functionalbeneﬁtofICinfusionofBMSCcomparedwiththe
standard treatment alone. Probably,the simplest approach to
myocardial cell therapy in the clinical setting is the transfer
of BM mononuclear cells into the myocardium. However,
using unmodiﬁed marrow or unselected mononuclear cells
can prevent the delivery of the “ideal” cell for myocardial
regeneration that could be available in a small number or
lost during the preparation process. In addition, few of the
unselected mononuclear cells could formally meet the stem
cell criteria and the vast majority are leukocytes that may
primarily induce local inﬂammation, rendering the actual
stem cell eﬀects insigniﬁcant. Selected CD133+ BM cell
population contains a small proportion of clonogenic cells,
which have a very high potential to induce neoangiogenesisBone Marrow Research 5
[18]. Furthermore, there is accumulating evidence that the
CD133+/CD34− subpopulation includes multipotent stem
cells with a signiﬁcant potential for diﬀerentiation into
mesenchymal and other nonhematopoietic lineages.
Therefore, Bartunek et al. conducted a phase I trial [12]
testing the IC injection of puriﬁed CD133+ BMSC into the
acutely infracted myocardium after successful stenting of the
culprit artery. They showed a signiﬁcant improvement in the
LV function in parallel with an increase in the myocardial
perfusion and viability suggesting a potent angiogenic eﬀect
of the injected cells. However, the following safety concerns
in the cell-treated group were reported: ﬁrst a small but
signiﬁcant rise in the CRP, second ventricular arrhythmias
were observed in 4 treated patients, and third a higher rate of
in-BMS restenosis and de novo lesion was found. Moreover,
they raised the possibility of a “Janus-like” eﬀect where they
reported in a retrospective analysis a signiﬁcant reduction of
the luminal diameters and epicardial conductance of the IR
artery, asassessed fromthepressure-derivedFFR[13]m ain ly
in early compared to late IC CD133+ cells administration
[17] which seems to be consistent with a higher risk for
atherosclerosis progression. Yet, these data were obtained
from retrospective analysis; they lack proper randomized
controlsandsystematicuseofICultrasoundimagingtotrack
changes in the vascular wall.
Accordingly, we initiated the COMPARE-AMI trial,
a randomized, double-blind, controlled study testing the
safety, feasibility, and functional eﬀect of the IC injection
of CD133+ cells as compared to placebo in relatively high-
risk patients with acute MI and persistent LV dysfunction.
The safety and functional eﬀect will be addressed using
time frames that are consistent with clinical applicability
and emerging safety proﬁle. To date twenty patients were
successfully randomized and treated, eighteen completed 4
months of followup, and thirteen of them reached one year
offollowup.Herein,wearepresentingourﬁrstsafetyanalysis
where we did not observe any major adverse events such as
death, stroke, MI, angina, heart failure, or stent thrombosis
within the ﬁrst 12 months following randomization. One
patient stopped his medication for one week and was
hospitalized for heart failure. In parallel with other trial
results, [12, 16] we did not report any complication related
to the BM harvest or the technique of IC infusions. Cardiac
enzymes levels remained unchanged during the initial 24
hours following injection. Furthermore, and in contrary to
what was reported in the Bartunek trial [12], neither the
WBC counts nor the CRP levels increased. Additionally,
no sustained ventricular arrhythmias were recorded and
none of the randomized patients required an implantable
cardioverter-deﬁbrillator. However, the serial 24-hour ECG
monitoring revealed a temporary signiﬁcant increase in the
number of isolated VPB at 4 months that spontaneously
decreased at 12 months of followup suggesting a transient
electrical irritability that could be related to the ischemic
burden in the ﬁrst months after the MI. Of note, only 5
patients had at least one run of NSVT until one year of
followup. On the other hand, all randomized patient had
a coronary angiogram control at 4 months after the IC
injection; no in-DES restenosis was reported; however three
over ﬁve patients treated with a BMS had a signiﬁcant but
asymptomatic restenosis requiring restenting with a DES
because of a documented signiﬁcant ischemia in the target
territory. Interestingly, no de novo lesion was reported at 4-
month followup, and no signiﬁcant diﬀerence was found in
the delta FFR as compared to baseline in the culprit versus
nonculprit artery suggesting the absence of any acceleration
of atherosclerosis. Finally, the 4-month echocardiography
assessment showed a signiﬁcant increase in the LVEF supe-
rior to what we observed in the placebo groups of the
randomized trials [4–7] suggesting a potential eﬀect on the
cardiac recovery in the CD 133+ injected patients.
In conclusion, the proposed experimental protocol in
which IC autologous CD133+ cells are injected after acute
MI is safe, without any serious adverse events up to one
year of followup. In addition, a potential beneﬁcial eﬀect
on the LV recovery of the enrolled patients is observed.
Final results will be available 1 year after the last patient has
been randomized; meanwhile the presented one-year safety
results justify the continuation of the COMPARE-AMI trial.
This randomized clinical study should help to support the
therapeutical potential of CD133+ cells for the treatment of
the infracted myocardium.
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